Treatment of pulmonary hypertension with GLY, an HMGB1 inhibitor, has the potential to attenuate pulmonary vascular remodeling and disease progression of pulmonary hypertension. The gene discussed is HMGB1; the disease is pulmonary arterial hypertension.